大咖对话「特别续集 part2」(音频)：对话肝脏病理KOL

Special Episode (PART 2) - Conversation with KOL Liver Pathologists

Our guest KOL liver pathologists continue their conversation from Part 1 following the FDA Webcast, by responding to more questions by Pharma companies and clinical investigators on how AI Digital Pathology (AI-DP) can aid pathologists with precise assessment to better interpret the disease biology of NASH. 

We’d like to thank our Guests and Moderator for their kind participation and professional views!

Guests

Prof. Pierre Bedossa,

Professor of Pathology at the University of Paris; Consultant in Liver Pathology at LIVERPAT, Paris, France

Prof. Zachary Goodman,

Director of Hepatic Pathology Consultation and Research,Inova Fairfax Hospital, Falls Church, Virginia, USA

Prof. David Kleiner,

Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, Center for Cancer Research,

National Cancer Institute, Bethesda, Maryland, USA

Moderator

Dr. Nikolai Naoumov, Adviser for Clinical Research and Drug Development in Liver Diseases, Novartis Pharma AG.

Key Takeaways from the KOLs in this Special Episode (Part 2)

- According to the KOLs, regression of disease is not well delineated or understood. AI-DP offers new insights into the biology of NASH and additional information especially in the identification of ballooned hepatocytes, quantification of peri-sinusoidal fibrosis, septa quantification and others.

- In the assessment of disease biology, it was highlighted that AI-DP can identify morphological/pathological features that cannot be detected by the human eye. This is an area where AI-DP plays a complementary role by providing precise details on liver architecture and reproducible quantitation with new parameters.

- It was stated that it is not appropriate to attempt to quantitate ratio of different patterns like F1 to F4 in a single specimen, as the pathology objective is to provide an integrated assessment.

- It was recommended that the role of AI-DP and the information it provides be regarded as an aid to extend the outputs of pathologists. Instead of being perceived as a replacement of pathologists, AI-DP could be seamlessly integrated into the pathologists’ daily workflow.

We hope that you will enjoy Part 1 and 2 of our Special Episode.

往期

关于我们

新加坡医疗科技公司HistoIndex，是杭州筹图科技有限公司的母公司，我们利用人工智能的图像分析技术和全球独创的无染色成像技术相结合应用于疾病进展的评价，特别是NASH新药开发的病理评价中。目前该技术平台已经在NASH临床前的多个动物模型和多个II，III期临床试验上做了深入研究和算法验证，已经参与完成近四十家国际国内知名药企、大型CRO公司和科研机构主办的相关试验。

想了解更多？
那就赶紧来关注我们

长按二维码 关注我们

有问题请联系我们
   热线电话：
 4009-6565-83